o Revenue of €2.1m in Q2 2023, stable compared to Q2 2022
o Continued momentum in sales of the new Medical Equipment activity
o First results of the technological alliance concluded with Sanyou Medical
Bordeaux, Boston, July 11, 2023 – 6:00 p.m. CEST: IMPLANET (Euronext Growth: ALIMP, FR0013470168, eligible for PEA-PME), a medical technology company specializing in implants for orthopedic surgery and in the distribution of technological medical equipment, today announces its revenue for the first half of 2023.
If you wish to receive all of the company’s financial communications in real time, you can register directly by email at the following address: [email protected]